

Philip A Philip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5512658/publications.pdf>

Version: 2024-02-01

67
papers

3,243
citations

186265

28
h-index

155660

55
g-index

70
all docs

70
docs citations

70
times ranked

5466
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Groupâ€œDirected Intergroup Trial S0205. <i>Journal of Clinical Oncology</i> , 2010, 28, 3605-3610.	1.6	570
2	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2784-2796.	1.6	267
3	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 805-812.	3.4	169
4	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2021, 7, 421.	7.1	159
5	Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 285-294.	8.1	152
6	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. <i>Oncotarget</i> , 2017, 8, 86356-86368.	1.8	147
7	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. <i>Oncologist</i> , 2018, 23, 1319-1327.	3.7	131
8	The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 57-74.	1.6	91
9	Dual blockade of epidermal growth factor receptor and insulinâ€œlike growth factor receptorâ€œ1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). <i>Cancer</i> , 2014, 120, 2980-2985.	4.1	78
10	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 76-87.	4.1	69
11	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3096-3103.	7.0	65
12	A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. <i>Future Oncology</i> , 2019, 15, 3189-3196.	2.4	64
13	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	4.5	64
14	Molecular Characterization of <i>KRAS</i> Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2704-2714.	7.0	57
15	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	10.7	51
16	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. <i>Cancer Treatment Reviews</i> , 2019, 77, 1-10.	7.7	48
17	miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. <i>American Journal of Pathology</i> , 2019, 189, 58-70.	3.8	46
18	Ras and exosome signaling. <i>Seminars in Cancer Biology</i> , 2019, 54, 131-137.	9.6	44

#	ARTICLE	IF	CITATIONS
19	Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. <i>Oncotarget</i> , 2017, 8, 82144-82155.	1.8	43
20	Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. <i>American Journal of Cancer Research</i> , 2015, 5, 1251-64.	1.4	42
21	Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. <i>Cancer Letters</i> , 2014, 351, 134-142.	7.2	41
22	Targeting KRAS in pancreatic cancer: new drugs on the horizon. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 819-835.	5.9	41
23	Gastrointestinal stromal tumor: a review of current and emerging therapies. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 625-641.	5.9	39
24	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020, 140, 119-129.	2.8	37
25	The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 131-148.	2.4	36
26	Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR) Tj ETQq0,0,0 rgBT /Overlock 1	4.6	34
27	F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities. <i>Seminars in Cancer Biology</i> , 2016, 36, 95-104.	9.6	29
28	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019, 24, 319-326.	3.7	29
29	Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4826.	4.1	29
30	Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. <i>Scientific Reports</i> , 2015, 5, 16077.	3.3	28
31	Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 1338-1348.	7.0	28
32	Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. <i>Cancers</i> , 2020, 12, 750.	3.7	27
33	Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. <i>Small GTPases</i> , 2019, 10, 367-377.	1.6	26
34	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000942.	4.5	26
35	Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. <i>Oncologist</i> , 2015, 20, 907-914.	3.7	25
36	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2019, 11, 1902.	3.7	22

#	ARTICLE	IF	CITATIONS
37	Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 535-546.	1.8	22
38	Abstract 5703: Up-regulation of miR-146a contributes to the inhibition of invasion of pancreatic cancer cells. <i>Cancer Research</i> , 2010, 70, 5703-5703.	0.9	22
39	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021, 40, 4894-4905.	5.9	19
40	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. <i>Oncogene</i> , 2022, 41, 3455-3460.	5.9	19
41	Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. <i>Cancers</i> , 2021, 13, 2777.	3.7	18
42	Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 225-227.	2.3	17
43	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 1320-1328.	1.7	16
44	Targeted therapies for pancreatic cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, S16-9.	0.7	15
45	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	4.1	14
46	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1836-1845.	4.1	14
47	Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. <i>Cancers</i> , 2021, 13, 4161.	3.7	14
48	Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 35-40.	0.6	13
49	Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. <i>Acta Oncologica</i> , 2016, 55, 303-308.	1.8	13
50	Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials. <i>Clinical Cancer Research</i> , 2014, 20, 4176-4185.	7.0	12
51	PET Scans as a Predictive Marker of Survival in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 35-40.	2.3	12
52	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C Mutant Cancers. <i>Cancer Research Communications</i> , 2022, 2, 342-352.	1.7	12
53	Novel Targets for Pancreatic Cancer Therapy. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 419-429.	1.5	10
54	A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil) in Pancreatic Cancer. <i>Journal of Pancreatic Cancer</i> , 2019, 5, 35-42.	0.9	10

#	ARTICLE	IF	CITATIONS
55	DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2019, 11, 1101.	3.7	9
56	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 95.	5.4	9
57	Targeting macrophages to treat pancreatic cancer. <i>Lancet Oncology</i> , The, 2016, 17, 552-553.	10.7	7
58	Molecular characterization of squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2423-2437.	1.4	7
59	Phase II study of CI-958 in colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 162-164.	2.3	4
60	Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 243-246.	1.3	4
61	Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS. <i>Cells</i> , 2021, 10, 1275.	4.1	4
62	Association of Homologous Recombinationâ€™DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 227-236.	4.1	4
63	Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 160-168.	1.3	3
64	First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 37-9.	0.7	2
65	Classification of early-stage colon cancer with ImmunoscoreÂ®: clinical evidence and case studies. <i>Future Oncology</i> , 2022, 18, 613-623.	2.4	2
66	Reply to A. Aref et al and E. Ben-Josef et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 1566-1567.	1.6	0
67	Pancreatic cancer: why we must be optimistic?. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 659-660.	5.9	0